<DOC>
	<DOCNO>NCT01739283</DOCNO>
	<brief_summary>Investigation Glucose-dependent Insulinotropic Polypeptide ( GIP ) effect hyper hypoglycemia type 1 diabetes .</brief_summary>
	<brief_title>GIP GLP-1 Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Hypoglycemia</mesh_term>
	<criteria>• Diagnosed type 1 diabetes ( WHO criteria ) HbA1c &gt; 9 % Liver disease ( ALAT/ASAT &gt; 2 x upper normal limit ) Diabetic nephropathy ( screatinine &gt; 130 µM albuminuria ) Proliferative diabetic retinopathy ( anamnestic ) Severe arteriosclerosis heart failure ( NYHA group III IV ) Anemia treatment medication applicable pause 12 hour Cpeptide increase 50 g iv arginine</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>